Using glycome databases for drug discovery

Background: The glycomics field has made great advancements in the last decade due to technologies for their synthesis and analysis including carbohydrate microarrays. Accordingly, databases for glycomics research have also emerged and been made publicly available by many major institutions worldwide. Objective: This review introduces these and other useful databases on which new methods for drug discovery can be developed. Methods: The scope of this review covers current documented and accessible databases and resources pertaining to glycomics. These were selected with the expectation that they may be useful for drug discovery research. Results/conclusion: There is a plethora of glycomics databases that have much potential for drug discovery. This may seem daunting at first but this review helps to put some of these resources into perspective. Additionally, some thoughts on how to integrate these resources to allow more efficient research are presented.     

中国人民解放军第九五医院2002年精神药品处方分析

目的:分析中国人民解放军第九五医院精神药品用药情况,指导精神药品的合理使用。方法:选取2002年全年精神药品处方,以限定日剂量(DDD)和药物利用指数(DUI)为指标的分析方法,进行用药分析。结果:12种精神药品中,8种药物的DUI<1.0,4种>1.0。结论:我院精神药品使用基本合理,部分用药需引起重视。     

Creating medical and drug code lists to identify cases in primary care databases

This paper demonstrates how compilation of medical and drug code lists for outcomes or exposures of interest for studies using primary care databases can be carried out efficiently using Stata. Use of Stata do‐files to record and execute the commands provides good documentation and ease of replication of the procedure. Copyright © 2009 John Wiley & Sons, Ltd.     

在药物动力学中立体选择性因素对药物相互作用的影响

综述了近几年对映体/对映体、对映体/片用药物在药动学中的相互作用.提出药动学相互作用研究中考虑立体选择性因素具有十分重要的临床意义,例如,避免相互作用引起的不良反应、增加治疗效果、理解血药浓度量效关系不一致现象以及提供研究生长点以进一步探求代谢处置机理等.应加强对立体选择性药动学相互作用的研究.     

Elite athletes' estimates of the prevalence of illicit drug use: evidence for the false consensus effect

Introduction and Aims. The false consensus effect (FCE) is the tendency for people to assume that others share their attitudes and behaviours to a greater extent than they actually do. The FCE has been demonstrated for a range of health behaviours, including substance use. The study aimed to explore the relationship between elite athlete's engagement in recreational drug use and their consensus estimates (the FCE) and to determine whether those who engage in the behaviour overestimate the use of others around them. Design and Method. The FCE was investigated among 974 elite Australian athletes who were classified according to their drug use history. Results. Participants tended to report that there was a higher prevalence of drug use among athletes in general compared with athletes in their sport, and these estimates appeared to be influenced by participants' drug use history. While overestimation of drug use by participants was not common, this overestimation also appeared to be influenced by athletes' drug use history. Discussion and Conclusions. The results suggest that athletes who have a history of illicit drug use overestimate the prevalence of drug use among athletes. These findings may be helpful in the formulation of normative education initiatives.[Dunn M, Thomas JO, Swift W, Burns L. Elite athletes' estimates of the prevalence of illicit drug use: Evidence for the false consensus effect. Drug Alcohol Rev 2012;31:27–32]     

映射法分析药物联合治疗的相互作用(英文)

目的:在联合药物治疗中,建立一种分析药物相互作用的新方法。方法:基于联合用药的量效关系曲线和等效性检验的原理,建立一种新的数学模型:Q=(E_o-E_t》/L(-1相似文献   

BindingDB and ChEMBL: online compound databases for drug discovery

Public domain repositories of compound structures and activity data are indispensable tools for many aspects of pharmaceutical research, especially in academic environments. Such databases provide essential resources for structure-activity data mining and the evaluation of chemoinformatics and drug design methods. They are also important to support scientific interactions between commercial and academic environments. This editorial highlights two major public domain compound data repositories, BindingDB and ChEMBL, which have different origins. BindingDB has evolved in an academic setting (and continues to be developed there) and ChEMBL in a biotechnology environment. The ChEMBL database is now maintained and further developed at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory. These databases mostly contain structures and activity data taken from the scientific literature, covering different stages of compound exploration and optimization efforts, and provide a substantial body of complementary compound activity information. Together with PubChem bioassays, ChEMBL and BindingDB provide the foundation of compound data analysis in the public domain.     

260例中药不良反应文献分析

目的 :对中药引起的不良反应进行统计分析 ,为临床使用中药提供参考。方法 :对 1 998～2 0 0 2年间国内主要医药期刊报道的中药不良反应2 60例进行数据收集分析。结果 :中药引起的不良反应涉及的品种较广 ,ADR发生率以注射剂最多(占 60 .4% ) ,过敏反应最为常见 (占 5 2 .7% )。结论 :加强中药ADR的宣传 ,合理使用中药 ,尽量避免或减少ADR的发生。     

新型冠状病毒肺炎临床合理用药专家共识

新型冠状病毒肺炎（coronavirus disease 2019,COVID-19）疫情发生以来,全国医院药学工作者坚持医药协同,在保障药品供应的前提下,积极参与临床救治工作,加强对患者的用药教育和指导,有效提高药物治疗水平,改善临床救治效果。为更好地发挥药学服务在COVID-19疫情防控中的重要作用,中国药学会医院药学专业委员会特组织临床和药学专家,在《新型冠状病毒感染的肺炎诊疗方案（试行第七版）》的基础上,参考国内外最新的诊疗方案和研究成果,并结合国内各地COVID-19患者的救治经验,制定出新型冠状病毒肺炎临床合理用药专家共识。本共识详细阐述COVID-19临床救治的九类用药,内容涵盖药物治疗作用、遴选原则、用法用量、不良反应及注意事项,以期为COVID-19临床用药提供参考。     

美国食品药品监督管理局复方制剂非临床安全性评价指导原则介绍

研发复方制剂旨在通过联合用药提高疗效和(或)降低单药的某些不良反应。因为药物间可能产生多种相互作用,如药动学、药效学、毒理学、化学的相互作用,所以复方制剂非临床安全性评价应重点关注单药间相互作用可能带来的安全性问题。本文根据FDA复方制剂非临床安全性评价指导原则草案,对复方制剂非临床安全性评价中的考虑要点如组方类型、可能的相互作用、附加实验研究等进行介绍,以期对我国复方制剂的非临床安全性研究和评价提供一些技术思路,供大家参考。